



18 March 2019

Customer Update re: I123mIBG

ANSTO has experienced an equipment failure within our nuclear medicine processing facility which will impact our ability to supply our locally produced I123 mIBG. This equipment failure does not impact any other products.

This has impacted our ability to supply I123 mIBG for this week and next week's doses and we will inform all our customers of the expected outage length as soon as possible"

In the short term, we have the option available to import I123 mIBG units from Japan to assist in covering the shortfall where the flights can enable timely delivery. This product will be supplied in line with SAS rules, as the product is not currently approved for use in Australia.

We will be in contact with all customers again on Monday 25th March with an update on when ANSTO will be able to restore local production of I123mIBG.

If you have any questions, please contact ANSTO directly on 1800 251 572